NCT06779929Completed
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Comparative Study of Tirzepatide vs Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 18 Sept 2026
Brief summary (registry, in English)
This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 70000 (actual)
- First submitted
- 10 Jan 2025
- Start date
- 1 Nov 2024
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Coronary artery disease, Stroke, Type 2 diabetes
- NCT number
- NCT06779929
What you commit to
- Study type: Observational
- Participants enrolled: 70000
- From 1 Nov 2024 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with any previous organ transplants
- Patients with gastroparesis, bowel obstruction or bariatric surgery
- Previous exposure to GLP-1RA or pramlintide during the 180-days washout period and including treatment initiation date
Other illness
- Patients with Type 1 diabetes mellitus
- Patients with history of proliferative diabetic retinopathy, panretinal photocoagulation, vitreous hemorrhage, or intravitreal anti-VEGF injection
- Patient within history of left ventricular assisted device (LVAD) or heart transplant
- Patient with CKD Stage 5, end stage kidney disease, kidney transplant, or hemodialysis
- Patients with multiple endocrine neoplasm syndrome type 2 (MEN-2)
- Patient with cancer
- Patients with acute hepatitis within the last year to treatment initiation
- Patients with hospitalization for heart failure within the last 60 days to treatment initiation
- Patient with acute coronary syndrome, ischemic stroke, peripheral arterial disease, or coronary or cerebrovascular procedure within the last 60 days to treatment initiation
Lab values
- Patients with elevated serum calcitonin level within the last year to treatment initiation
Age
- Patients with missing age or sex information
Other
- Patients with acute of chronic pancreatitis
- Pregnant women
- Patient with diabetic ketoacidosis or HONK within the last year to treatment initiation
- Patients with severe hypoglycemia within the last 6 months to treatment initiation
- Patients with prescription dispensing for both tirzepatide and dulaglutide on treatment initiation date
Who the study is looking for
- Patients with T2D who were new users of tirzepatide or new users of dulaglutide
- AND established ASCVD defined as:
- History of Myocardial Infarction (MI) or MI sequela
- Unstable or stable angina
- Coronary atherosclerosis disease or procedures
- Ischemic stroke
- Peripheral arterial disease or procedures
- Atherosclerotic cerebrovascular disease or cerebrovascular procedures
- Lower-limb amputation
- Age \>= 40 years old
- Patients with at least 180 days of continuous health plan enrollment before and including the treatment initiation date
Age in the registry: 40 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.